ANTIDEPRESSANT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Antidepressant Market, By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs) (Fluoxetine, Sertraline, and Others), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (Venlafaxine, Duloxetine, and Others), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), and Atypical Antidepressants), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Aug 2024
Code : CMI7243
Pages :167
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Antidepressant Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

New and innovative drug development

The need for new and better therapeutic options has always been a driving force behind pharmaceutical research and development. In the case of antidepressants as well, the need for innovation has remained a major factor motivating growth. While several effective medicines are available today for treating depression, limitations and unmet needs still exist. Existing drugs may not work well for around 30 percent of patients or may have troubling side effects for some that lead to non-adherence or discontinuation of treatment. Also, the onset of action is often slow with standard antidepressants. This has prompted companies to invest heavily in their pipeline of new chemical entities and novel mechanism antidepressants. The goal is to develop drugs that are faster acting, more tolerable and effective for more types of patients than existing options. There is a particular focus on developing drugs that directly target pathways implicated in depression like glutamate, GABA, and neurotrophic factors in addition to the serotonergic and noradrenergic systems traditionally targeted. Investigational compounds in Phase II and III trials include agents aimed at glutamatergic, orexinergic, and neuroplasticity targets. If successful, these innovative new treatments coming to market would provide clearer therapeutic advantages over older drugs and potentially capture more market share. They could also expand the overall antidepressant market size by making treatment a more positive experience for more individuals and their doctors. The launch of each new drug thus enables companies to gain new revenues and extends the product life cycle of their antidepressant portfolio. This continuous market need for novel innovation hence remains a very important driver behind the ongoing efforts and investments in antidepressant R&D.

Key Players Insights